HSP90AA1 and cancer: Similarly, the same client proteins from the mitogenic pathway in cells exhibited unexpected and heterogenous reactions among eight randomly selected cancer cell lines in response to the Hsp90 ATP-binding inhibitor, inconsistent with the classical understanding.